Silo Pharma buys software assets from Larry King for stock

Silo Pharma, Inc. disclosed in an 8-K that on October 13, 2026, the company entered into an asset purchase agreement with Larry King, identified as the seller.¹ Under the terms of that agreement, the seller agreed to sell and Silo Pharma agreed to buy certain software and related intellectual property, described in the filing as the purchased assets.¹

As payment, the company issued the seller 150,000 shares of its common stock, par value $0.0001 per share.¹ Those shares carry trading restrictions: the shares are subject to a lock-up period starting on the agreement's effective date and ending at the earliest of twelve months after that date, a change in control as defined in the agreement, or written consent from the company.¹ During that lock-up window, King cannot sell, transfer, hedge, pledge, or otherwise dispose of the shares, or enter into any transaction that shifts the economic risk of owning them, without Silo Pharma's prior written consent.¹

The filing notes the agreement includes representations, warranties and covenants standard for this type of deal, and that King agreed to indemnify Silo Pharma for misrepresentations, breaches, third-party infringement claims tied to the software, or any gross negligence, fraud, or intentional misconduct on his part.¹

Regarding securities law compliance, the share issuance to King was made under the exemption provided by Section 4(a)(2) of the Securities Act of 1933.¹

The full agreement was filed as Exhibit 10.1, dated October 13, 2026, between the company and Larry King.¹ The 8-K was signed by Eric Weisblum, Chief Executive Officer, and dated October 14, 2026.